2.07 USD
+0.14 (+7.25%)
2.12 USD
+0.05 (+2.42%)
Taking everything into account, IPA scores 2 out of 10 in our fundamental rating. IPA was compared to 57 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of IPA have multiple concerns. IPA is quite expensive at the moment. It does show a decent growth rate.
1. Profitability
1.1 Basic Checks
In the past year IPA has reported negative net income.
IPA had a negative operating cash flow in the past year.
IPA had negative earnings in each of the past 5 years.
In the past 5 years IPA always reported negative operating cash flow.
1.2 Ratios
IPA has a Return On Assets of -68.03%. This is amonst the worse of the industry: IPA underperforms 89.09% of its industry peers.
IPA has a Return On Equity of -127.97%. This is amonst the worse of the industry: IPA underperforms 83.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -68.03% | ||
| ROE | -127.97% | ||
| ROIC | N/A |
ROA(3y)-49.16%
ROA(5y)-35.25%
ROE(3y)-84.68%
ROE(5y)-57.83%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
IPA's Gross Margin of 55.25% is fine compared to the rest of the industry. IPA outperforms 65.45% of its industry peers.
IPA's Gross Margin has been stable in the last couple of years.
IPA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 55.25% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.87%
GM growth 5Y-0.67%
2. Health
2.1 Basic Checks
IPA does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for IPA has been increased compared to 1 year ago.
The number of shares outstanding for IPA has been increased compared to 5 years ago.
The debt/assets ratio for IPA is higher compared to a year ago.
2.2 Solvency
IPA has an Altman-Z score of -0.35. This is a bad value and indicates that IPA is not financially healthy and even has some risk of bankruptcy.
IPA's Altman-Z score of -0.35 is on the low side compared to the rest of the industry. IPA is outperformed by 76.36% of its industry peers.
A Debt/Equity ratio of 0.49 indicates that IPA is not too dependend on debt financing.
IPA's Debt to Equity ratio of 0.49 is on the low side compared to the rest of the industry. IPA is outperformed by 63.64% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -0.35 |
ROIC/WACCN/A
WACC10.11%
2.3 Liquidity
A Current Ratio of 2.08 indicates that IPA has no problem at all paying its short term obligations.
IPA's Current ratio of 2.08 is in line compared to the rest of the industry. IPA outperforms 43.64% of its industry peers.
A Quick Ratio of 1.85 indicates that IPA should not have too much problems paying its short term obligations.
With a Quick ratio value of 1.85, IPA perfoms like the industry average, outperforming 47.27% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.08 | ||
| Quick Ratio | 1.85 |
3. Growth
3.1 Past
IPA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 34.78%, which is quite impressive.
IPA shows a small growth in Revenue. In the last year, the Revenue has grown by 0.01%.
The Revenue has been growing by 11.77% on average over the past years. This is quite good.
EPS 1Y (TTM)34.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.55%
Revenue 1Y (TTM)0.01%
Revenue growth 3Y8.19%
Revenue growth 5Y11.77%
Sales Q2Q%8.08%
3.2 Future
Based on estimates for the next years, IPA will show a very strong growth in Earnings Per Share. The EPS will grow by 39.31% on average per year.
Based on estimates for the next years, IPA will show a quite strong growth in Revenue. The Revenue will grow by 17.92% on average per year.
EPS Next Y49.5%
EPS Next 2Y48.39%
EPS Next 3Y35.81%
EPS Next 5Y39.31%
Revenue Next Year13.46%
Revenue Next 2Y22.45%
Revenue Next 3Y19.46%
Revenue Next 5Y17.92%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for IPA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for IPA. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
A more expensive valuation may be justified as IPA's earnings are expected to grow with 35.81% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y48.39%
EPS Next 3Y35.81%
5. Dividend
5.1 Amount
No dividends for IPA!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
2.07
+0.14 (+7.25%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)
Earnings (Next)
Inst Owners8.61%
Inst Owner Change2.3%
Ins Owners1.19%
Ins Owner ChangeN/A
Market Cap95.53M
Revenue(TTM)24.52M
Net Income(TTM)-30.23M
Analysts80
Price Target5.1 (146.38%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)44.31%
Min EPS beat(2)0.99%
Max EPS beat(2)87.62%
EPS beat(4)3
Avg EPS beat(4)14.95%
Min EPS beat(4)-35.01%
Max EPS beat(4)87.62%
EPS beat(8)6
Avg EPS beat(8)14.05%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)0
Avg Revenue beat(2)-9.96%
Min Revenue beat(2)-12.4%
Max Revenue beat(2)-7.52%
Revenue beat(4)0
Avg Revenue beat(4)-12.13%
Min Revenue beat(4)-22.81%
Max Revenue beat(4)-5.81%
Revenue beat(8)3
Avg Revenue beat(8)-4.97%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)25%
PT rev (3m)25%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-10%
EPS NY rev (1m)-36.36%
EPS NY rev (3m)-36.36%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-2.34%
Revenue NY rev (1m)-0.6%
Revenue NY rev (3m)-0.6%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 5.4 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 5.6 | ||
| P/tB | 9.23 | ||
| EV/EBITDA | N/A |
EPS(TTM)-0.22
EYN/A
EPS(NY)-0.11
Fwd EYN/A
FCF(TTM)-0.11
FCFYN/A
OCF(TTM)-0.1
OCFYN/A
SpS0.38
BVpS0.37
TBVpS0.22
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -68.03% | ||
| ROE | -127.97% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 55.25% | ||
| FCFM | N/A |
ROA(3y)-49.16%
ROA(5y)-35.25%
ROE(3y)-84.68%
ROE(5y)-57.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.87%
GM growth 5Y-0.67%
F-Score4
Asset Turnover0.55
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | 15.61% | ||
| Cap/Sales | 3.26% | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 2.08 | ||
| Quick Ratio | 1.85 | ||
| Altman-Z | -0.35 |
F-Score4
WACC10.11%
ROIC/WACCN/A
Cap/Depr(3y)20.78%
Cap/Depr(5y)25.53%
Cap/Sales(3y)5.4%
Cap/Sales(5y)5.87%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)34.78%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%54.55%
EPS Next Y49.5%
EPS Next 2Y48.39%
EPS Next 3Y35.81%
EPS Next 5Y39.31%
Revenue 1Y (TTM)0.01%
Revenue growth 3Y8.19%
Revenue growth 5Y11.77%
Sales Q2Q%8.08%
Revenue Next Year13.46%
Revenue Next 2Y22.45%
Revenue Next 3Y19.46%
Revenue Next 5Y17.92%
EBIT growth 1Y12.17%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-27.75%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-50.97%
OCF growth 3YN/A
OCF growth 5YN/A
IMMUNOPRECISE ANTIBODIES LTD / IPA FAQ
What is the ChartMill fundamental rating of IMMUNOPRECISE ANTIBODIES LTD (IPA) stock?
ChartMill assigns a fundamental rating of 2 / 10 to IPA.
Can you provide the valuation status for IMMUNOPRECISE ANTIBODIES LTD?
ChartMill assigns a valuation rating of 1 / 10 to IMMUNOPRECISE ANTIBODIES LTD (IPA). This can be considered as Overvalued.
What is the profitability of IPA stock?
IMMUNOPRECISE ANTIBODIES LTD (IPA) has a profitability rating of 1 / 10.
Can you provide the financial health for IPA stock?
The financial health rating of IMMUNOPRECISE ANTIBODIES LTD (IPA) is 2 / 10.
Can you provide the expected EPS growth for IPA stock?
The Earnings per Share (EPS) of IMMUNOPRECISE ANTIBODIES LTD (IPA) is expected to grow by 49.5% in the next year.